# First Tracks Biotherapeutics, Inc.: financial statements, quarterly

TRAX · Nasdaq · CIK 2091349 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/trax.md) · [Financials](/companies/trax/financials.md) · [Filings](/companies/trax/filings.md) · [Insiders](/companies/trax/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/trax/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development | $m | [41.5](/filings/0001193125-26-224190.md) | [39.3](/filings/0001193125-26-346931.md) | [34.0](/filings/0001193125-26-224190.md) | [25.6](/filings/0001193125-26-346931.md) |
| Operating income | $m | [(51.3)](/filings/0001193125-26-224190.md) | [(45.9)](/filings/0001193125-26-346931.md) | [(52.8)](/filings/0001193125-26-224190.md) | [(34.9)](/filings/0001193125-26-346931.md) |
| Net income | $m | [(47.2)](/filings/0001193125-26-346931.md) | [(42.4)](/filings/0001193125-26-346931.md) | [(50.5)](/filings/0001193125-26-346931.md) | [(33.4)](/filings/0001193125-26-346931.md) |
| Diluted EPS | $ per share | not reported | [(1.47)](/filings/0001193125-26-346931.md) | not reported | [(0.95)](/filings/0001193125-26-346931.md) |
| Basic EPS | $ per share | not reported | [(1.47)](/filings/0001193125-26-346931.md) | not reported | [(0.95)](/filings/0001193125-26-346931.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | [238](/filings/0001193125-26-346931.md) | [248](/filings/0001193125-26-224190.md) | [168](/filings/0001193125-26-346931.md) |
| Current assets | $m | not reported | not reported | not reported | [316](/filings/0001193125-26-346931.md) | [289](/filings/0001193125-26-224190.md) | [178](/filings/0001193125-26-346931.md) |
| Total assets | $m | not reported | not reported | not reported | [331](/filings/0001193125-26-346931.md) | [291](/filings/0001193125-26-224190.md) | [183](/filings/0001193125-26-346931.md) |
| Current liabilities | $m | not reported | not reported | not reported | [31.0](/filings/0001193125-26-346931.md) | [33.1](/filings/0001193125-26-224190.md) | [12.4](/filings/0001193125-26-346931.md) |
| Shareholders' equity | $m | [392](/filings/0001193125-26-346931.md) | [358](/filings/0001193125-26-346931.md) | [271](/filings/0001193125-26-346931.md) | [287](/filings/0001193125-26-346931.md) | [257](/filings/0001193125-26-346931.md) | [169](/filings/0001193125-26-346931.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(45.0)](/filings/0001193125-26-224190.md) | [(38.6) d](/filings/0001193125-26-346931.md) | [(32.6)](/filings/0001193125-26-224190.md) | [(31.9) d](/filings/0001193125-26-346931.md) |
| Capital expenditure | $m | [0.0](/filings/0001193125-26-224190.md) | [0.0 d](/filings/0001193125-26-346931.md) | [0.0](/filings/0001193125-26-224190.md) | [0.0 d](/filings/0001193125-26-346931.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-06-30) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [28.8](/filings/0001193125-26-346931.md) | [35.0](/filings/0001193125-26-346931.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 35,730,843 at 2026-08-07, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-346931.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.